GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Cyclically Adjusted Revenue per Share

Acorda Therapeutics (FRA:CDG) Cyclically Adjusted Revenue per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Acorda Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was €15.028. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Acorda Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Acorda Therapeutics was 16.70% per year. The lowest was -3.90% per year. And the median was 4.80% per year.

As of today (2024-06-08), Acorda Therapeutics's current stock price is €8.423. Acorda Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.00. Acorda Therapeutics's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Acorda Therapeutics was 7.96. The lowest was 0.01. And the median was 1.21.


Acorda Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Acorda Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Cyclically Adjusted Revenue per Share Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,305.77 894.59 916.67 850.89 -

Acorda Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 894.45 669.13 569.18 - -

Competitive Comparison of Acorda Therapeutics's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Cyclically Adjusted PS Ratio falls into.



Acorda Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Acorda Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=15.028/131.7762*131.7762
=15.028

Current CPI (Mar. 2024) = 131.7762.

Acorda Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 201.941 100.560 264.630
201409 232.935 100.428 305.645
201412 266.279 99.070 354.187
201503 263.606 99.621 348.691
201506 280.645 100.684 367.311
201509 364.765 100.392 478.799
201512 326.543 99.792 431.201
201603 279.040 100.470 365.987
201606 300.101 101.688 388.897
201609 319.659 101.861 413.539
201612 351.752 101.863 455.049
201703 292.215 102.862 374.355
201706 324.021 103.349 413.146
201709 309.018 104.136 391.040
201712 413.496 104.011 523.876
201803 221.907 105.290 277.730
201806 333.911 106.317 413.872
201809 311.430 106.507 385.319
201812 153.111 105.998 190.347
201903 98.639 107.251 121.195
201906 111.861 108.070 136.399
201909 109.424 108.329 133.108
201912 114.188 108.420 138.787
202003 63.894 108.902 77.315
202006 75.008 108.767 90.875
202009 32.544 109.815 39.052
202012 74.156 109.897 88.920
202103 51.148 111.754 60.312
202106 52.764 114.631 60.656
202109 48.004 115.734 54.658
202112 55.077 117.630 61.701
202203 30.861 121.301 33.526
202206 33.998 125.017 35.836
202209 27.295 125.227 28.723
202212 22.370 125.222 23.541
202303 17.082 127.348 17.676
202306 22.053 128.729 22.575
202309 20.909 129.860 21.218
202312 28.043 129.419 28.554
202403 15.028 131.776 15.028

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Acorda Therapeutics  (FRA:CDG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Acorda Therapeutics was 7.96. The lowest was 0.01. And the median was 1.21.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Acorda Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (FRA:CDG) Business Description

Industry
Traded in Other Exchanges
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines